246 related articles for article (PubMed ID: 28692178)
1. Cell-free DNA - Minimally invasive marker of hematological malignancies.
Kubaczkova V; Vrabel D; Sedlarikova L; Besse L; Sevcikova S
Eur J Haematol; 2017 Oct; 99(4):291-299. PubMed ID: 28692178
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
Soscia R; Della Starza I; De Novi LA; Ilari C; Ansuinelli M; Cavalli M; Bellomarino V; Cafforio L; Di Trani M; Cazzaniga G; Fazio G; Santoro A; Salemi D; Spinelli O; Tosi M; Terragna C; Robustelli V; Bellissimo T; Colafigli G; Breccia M; Chiaretti S; Di Rocco A; Martelli M; Guarini A; Del Giudice I; Foà R
Hematol Oncol; 2023 Feb; 41(1):50-60. PubMed ID: 36251440
[TBL] [Abstract][Full Text] [Related]
3. Role of cell-free DNA in haematological malignancies.
Lim JK; Kuss B; Talaulikar D
Pathology; 2021 Apr; 53(3):416-426. PubMed ID: 33648721
[TBL] [Abstract][Full Text] [Related]
4. The role of circulating free DNA in the management of NSCLC.
Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
[TBL] [Abstract][Full Text] [Related]
5. Applications of Circulating Tumor DNA in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Promises and Challenges.
Xue Y; Xia X; Liu X; Zheng Y; Gu H; Wang X
Front Biosci (Landmark Ed); 2024 Feb; 29(2):86. PubMed ID: 38420833
[TBL] [Abstract][Full Text] [Related]
6. The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies.
Colmenares R; Álvarez N; Barrio S; Martínez-López J; Ayala R
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267616
[TBL] [Abstract][Full Text] [Related]
7. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Deshpande S; Tytarenko RG; Wang Y; Boyle EM; Ashby C; Schinke CD; Thanendrarajan S; Zangari M; Zhan F; Davies FE; Morgan GJ; van Rhee F; Walker BA
Eur J Haematol; 2021 Feb; 106(2):230-240. PubMed ID: 33107092
[TBL] [Abstract][Full Text] [Related]
8. [Application of Liquid Biopsy for Lung Cancer Treatment.].
Mori S; Yatabe Y
Rinsho Byori; 2016 May; 64(4):407-411. PubMed ID: 29182807
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
10. Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA.
Thakral D; Gupta R; Sahoo RK; Verma P; Kumar I; Vashishtha S
Front Cell Dev Biol; 2020; 8():604391. PubMed ID: 33363162
[TBL] [Abstract][Full Text] [Related]
11. Cell-Free DNA in the Management of Colorectal Cancer.
Harlé A
Recent Results Cancer Res; 2020; 215():253-261. PubMed ID: 31605233
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive prenatal test identifies circulating cell-free DNA chromosomal abnormalities derived from clonal hematopoiesis in aggressive hematological malignancies.
Giudice V; Ianniello M; De Novellis D; Pezzullo L; Petrillo N; Serio B; D'Addona M; Della Corte AM; Rizzo M; Cuffa B; Castaldi MA; Savarese P; Mori A; Castiello R; Fico A; Savarese G; Selleri C
Clin Exp Med; 2024 Apr; 24(1):69. PubMed ID: 38578383
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.
Barbosa A; Peixoto A; Pinto P; Pinheiro M; Teixeira MR
Expert Rev Mol Med; 2018 Dec; 20():e6. PubMed ID: 30558693
[TBL] [Abstract][Full Text] [Related]
14. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
[TBL] [Abstract][Full Text] [Related]
16. MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.
Ikeda S; Schwaederle M; Mohindra M; Fontes Jardim DL; Kurzrock R
J Hematol Oncol; 2018 Jun; 11(1):76. PubMed ID: 29866143
[TBL] [Abstract][Full Text] [Related]
17. Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E; Fotiou D; Kastritis E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e905-e909. PubMed ID: 32723621
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
Sánchez R; Ayala R; Martínez-López J
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of del(20q) in patients with hematological malignancies.
Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.
Vrabel D; Sedlarikova L; Besse L; Rihova L; Bezdekova R; Almasi M; Kubaczkova V; Brožová L; Jarkovsky J; Plonkova H; Jelinek T; Sandecka V; Stork M; Pour L; Sevcikova S; Hajek R
Eur J Haematol; 2020 Mar; 104(3):190-197. PubMed ID: 31763708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
